Introduction The World Health Organization (WHO) recommends that human papillomavirus
(HPV) vaccination programs are established to be cost-effective before implementation …

Background The success of human papillomavirus (HPV) national immunization program
depends on effective strategies in optimizing the uptake of HPV vaccine. Given the …

Introduction: Human papillomavirus (HPV) is one of the world's most common sexually
transmitted infections, and has been associated with a number of cervical and non-cervical …

Background Human papillomavirus (HPV) infection can have severe consequences both in
women and men. Preadolescent girls are vaccinated against HPV worldwide but a gender …

Abstract Introduction In the United States, routine human papillomavirus (HPV) vaccination
is recommended for females and males at age 11 or 12 years; the series can be started at …

Introduction: Low and middle income countries (LMICs) bear more than 50% of the current
cervical cancer burden over the last decade with linkages to lack of HPV vaccination, high …

Background Cervical cancer is a major public health problem in Latin America. Cost-
effectiveness studies help stakeholders with decisions regarding human papillomavirus …

Introduction: Many economic evaluations of HPV vaccination have been published, but most
have focused on the prevention of cervical disease as a primary health outcome. The cost …

Vaccines to protect against human papillomavirus (HPV) infection are recommended for all
adolescents by the World Health Organization (WHO) and are primarily delivered in school …

Abstract Introduction In Hong Kong (HK), a single-cohort vaccination program for 10–12-
year-old girls with the 9-valent human papillomavirus (HPV) vaccine (9vHPV; types …